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Expression of V1A and GRP receptors leads to cellular
transformation and increased sensitivity to substance-P
analogue-induced growth inhibition
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Small-cell lung cancer (SCLC) is a particularly aggressive cancer, which metastasises early. Despite initial sensitivity to radio- and
chemo-therapy, it invariably relapses, so that the 2-year survival remains less than 5%. Neuropeptides particularly arginine vasopressin
(AVP) and gastrin-releasing peptide (GRP) act as autocrine and paracrine growth factors and the expression of these and their
receptors are a hallmark of the disease. Substance-P analogues including [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-substance-P (SP-D) and
[Arg6,D-Trp7,9,NmePhe8]-substance-P (6–11) (SP-G) inhibit the growth of SCLC cells by modulating neuropeptide signalling. We
show that GRP and V1A receptors expression leads to the development of a transformed phenotype. Addition of neuropeptide
provides some protection from etoposide-induced cytotoxicity. Receptor expression also leads to an increased sensitivity to
substance-P analogue-induced growth inhibition. We show that SP-D and SP-G act as biased agonists at GRP and V1A receptors
causing blockade of Gq-mediated Ca
2þ release while directing signalling to activate ERK via a pertussis toxin-sensitive pathway. This is
the first description of biased agonism at V1A receptors. This unique pharmacology governs the antiproliferative properties of these
agents and highlights their potential therapeutic potential for the treatment of SCLC and particularly in tumours, which have
developed resistance to chemotherapy.
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Lung cancer is the most common fatal malignancy in the
developed world. Small-cell lung cancer (SCLC), which constitutes
25% of the total, is a particularly aggressive form of lung cancer. It
metastasises early and over 90% of patients have widespread
metastasis at presentation precluding curative surgery. Despite
initial sensitivity to radio- and chemo-therapy, SCLC almost
invariably relapses, so that the 2-year survival remains less than
5% (Smyth et al, 1986). Small-cell lung cancer is a paradigm for
neuropeptide-driven tumourigenesis. Small-cell lung cancer cells
proliferate in response to a range of neuropeptide growth factors
and in many cases these neuropeptides are involved in autocrine
and paracrine growth loops, which fuel unrestrained proliferation
(Moody et al, 1981; Sethi and Rozengurt, 1991; Sethi et al, 1992;
North, 2000). This is thought to be part of a special process of
oncogenic transformation called Selective Tumour gene Expres-
sion of Peptides essential for Survival (STEPS) (North, 2000). The
expression of neuropeptides and their receptors in tumour cells
may render them sensitive to pharmacological therapeutic
intervention and may be of diagnostic importance for the early
detection of lung cancer and for the selection of appropriate
treatment. Much of the recent studies in SCLC have focused on the
roles of the specific mitogens gastrin-releasing peptide (GRP, the
mammalian homologue of bombesin) and arginine vasopressin
(AVP).
Gastrin-releasing peptide receptors are frequently aberrantly
expressed in human neuroendocrine tumours of the breast,
prostate, lung and colon (Carroll et al, 1999; Jensen et al, 2001)
where they have both mitogenic and morphogenic roles and confer
a survival advantage in proliferating cancer cells. It has been
suggested that the detection of these markers in the peripheral
blood of patients may be useful as early markers of SCLC.
Scintigraphy with the labelled peptide ligand 99mTc-bombesin/
GRP has been shown to detect prostate cancer and invasion of
pelvic lymph nodes and should be applicable to other endocrine
tumours particularly SCLC (De Vincentis et al, 2004). Monoclonal
antibodies have been developed against circulating bombesin and
one such antibody 2A11 has been shown to inhibit the growth of
SCLC in vitro and as xenografts in nude mice (Chaudhry et al,
1999); however, it has limited efficacy in human trials.
The presence of AVP and V1A receptors on SCLC tumours has
been extensively studied and the potential presence of an autocrine
growth loop has been established. Small-cell lung cancer patients
frequently display symptoms of inappropriate antidiuretic hor-
mone secretion such as hyponatremia and urinary hyperosmolality
(Johnson et al, 1997). Independent studies have shown the
expression of V1A receptors in five out of five SCLC lines and
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zero out of four non-small-cell lung cancer (NSCLC) lines (Ocejo-
Garcia et al, 2001) while we showed expression of V1A receptors in
four out of four SCLC lines (Waters et al, 2003). Expression of V1A
receptors and vasopressin is the most useful diagnostic tool for
differentiating SCLC from NSCLC and other cancers (Coulson et al,
2003). Therapy that targets V1A receptors may be of potential
benefit for SCLC. Small-cell lung cancer cells can also express the
AVP gene as provasopressin, which remains attached to the cell
membrane and conceivably contributes to the autocrine-driven
mitogenesis (Friedmann et al, 1994). Antibodies recognising this
cell surface antigen have been developed as a potential diagnostic
and therapeutic tool that targets SCLC tumours in vivo (Keegan
et al, 2002).
However, the main focus of research in this drug development
strategy has been in the development of broad-spectrum
neuropeptide antagonists. Synthetic analogues of substance-P for
example, [Arg6,D-Trp7,9,NmePhe8]-substance-P (6– 11) (SP-G) were
initially identified as antagonists of substance-P-mediated cellular
effects and were subsequently found to also antagonise the cellular
effects of bombesin (Jensen et al, 1984). SP-G and its analogue SP-
D inhibit calcium mobilisation stimulated by bombesin and
vasopressin in SCLC cells (Woll and Rozengurt, 1988; Langdon
et al, 1992; Sethi et al, 1992). They also inhibit mitogenesis by the
same neuropeptides in both Swiss 3T3 cells and SCLC cells (Woll
and Rozengurt, 1988; Sethi et al, 1992; Seckl et al, 1995) In addition
to the in vitro growth inhibitory effects of substance-P analogues,
these compounds inhibit the growth of tumours in xenograft
models in nude mice (Langdon et al, 1992) and are more effective
than specific neuropeptide receptor antagonists. SP-G has recently
completed a phase I clinical trial where it shows minimal toxicity
at therapeutic plasma concentrations (Clive et al, 2001). However,
its mechanism of action is still being investigated.
Our previous work has shown that SP-G and SP-D do not act as
simple competitive antagonists of GRP receptors but rather act as
biased agonists, inhibiting GRP-stimulated PLC activation via Gq
while directly stimulating JNK and ERK via G12 and Gi, respectively
(Tallet et al, 1996; Jarpe et al, 1998; MacKinnon et al, 1999, 2001)
The prolonged stimulation of JNK and ERK coupled with an
inhibition of intracellular Ca2þ is fundamental for the antiproli-
ferative and proapoptotic effects of these agents (MacKinnon et al,
2001, Waters et al, 2003). It is not known whether these compounds
interact with vasopressin receptors in the same fashion.
It was the objective of the present study to examine the effect of
GRPr and V1Ar expression, the two most common neuropeptide
receptors present on SCLC, on growth and transformation of the
epithelial cell line, CHO-K1. We show that expression of these
receptors leads to an increase in basal and anchorage-independent
growth in low serum, and an increased sensitivity to substance-P
analogues. As well as directing GRP receptor signalling, substance-
P analogues also act as biased agonists at V1A vasopressin
receptors. These combined effects will be useful for SCLC therapy
and particularly in targeting well-differentiated tumours, which
have developed resistance to chemotherapy.
METHODS
Materials
CHO-K1 cells were purchased for the European Cell Culture
Collection; Dulbecco’s modified Eagle’s medium (DMEM), GRP,
bombesin and monoclonal antibody to diphosphorylated ERK 1 and
2 (M 8159) were from Sigma (Poole, UK); ([D-Arg1,D-Phe5,D-
Trp7,9,Leu11]-substance-P (SP-D) and [D-Arg6,D-Trp7,9,NmePhe8]-
substance-P (6–11) (SP-G) were synthesised by Cancer Research
UK (London, UK). The human V1A receptor construct in pcDNA3.1
was a kind gift from M Thibonnier (Case Western Reserve
University School of Medicine, OH, US). The human GRP receptor
in pcDNA3.1 was from J Battey (Albert Einstein College of Medicine,
NY, USA). [125I]-Arginine vasopressin (2000 Ci mmol1) and [125I]-
GRP were from Amersham International (Amersham, UK).
Cell culture and transfection
CHO-K1 cells were maintained in DMEM supplemented with 10%
(v v1) foetal bovine serum (heat-inactivated at 571C for 1 h)
50 U ml1 penicillin, 50mg ml1 streptomycin and 5 mg ml1 L-
glutamine in a humidified atmosphere of 5% CO2:95% air at 371C.
CHO-K1 cells were transfected with full-length human GRP
receptor or human V1A receptor using lipofectamine plus
(Invitrogen) as per the manufacturer’s instructions. Stable cell
cultures were maintained in the presence of 400 mg ml1 G418-
sulphate.
Receptor binding
Receptor binding was carried out in confluent and quiescent
cultures of CHO-K1-V1Ar and GRPr cells in a binding medium
containing DMEM, 1 mg ml1 bovine serum albumin and radi-
oligand (1.0 nM GRP containing 2nCi [125I]-GRP or 0.6 nM AVP
containing 45 nCi [125I]-AVP. Incubations were carried out at 371C
for 30 min in the presence of inhibitors as indicated. Nonspecific
binding was defined in the presence of 1 mM GRP or AVP,
respectively. The reaction was stopped on ice and unbound ligand
was removed by washing  3 with ice-cold phosphate-buffered
saline. After solubilisation in 0.1 M NaOH, 2% Na2C03 containing
1% SDS, bound ligand was estimated by liquid scintillation
counting. The binding parameters Kd and Bmax were calculated
from competition binding isotherms with unlabelled ligand
(DeBlasi et al, 1989). The IC50 (concentration of drug displacing
50% specific binding) was converted to the inhibitory constant
(Ki), where Ki¼ IC50/(1þ [ligand]/Kd) (Cheng and Prusoff, 1973).
Growth assays
Liquid growth Exponentially growing CHO-K1 cells were trypsi-
nised and suspended in DMEM with 5% FCS at a density of
5 104 cells per plate in the presence or absence of mediators in
triplicate. Cells were grown for 1 –9 days and cell number
determined using a Coulter Counter (model Z1, Coulter).
MTT assay In some assays, MTT (3-[4,5-dimethylthiazol-2yl]-
2,5-diphenyl tetrazolium bromide) formazan production (Sigma)
was used to measure proliferation as per the manufacturer’s
instructions.
Clonogenic assay CHO-K1 (2x104) viable cells were mixed with
DMEM containing 0.3% agarose in the presence or absence of
mediators and layered over a solid base of 0.5% agarose in DMEM
in 35 mm plastic dishes. The cultures were incubated at 371C for
1–10 days, and then stained with 1 mg ml1 nitro-blue tetrazolium
(NBT, Sigma) overnight at 371C. Colonies from 10 separate fields
were counted using a microscope with a  4 objective. Cloning
efficiency is calculated as the percentage of original number of
seeded cells forming colonies of 46 cells.
Aggregation assay CHO-K1 cells were suspended in DMEM in the
presence of 5% FCS and seeded into low adhesion tissue culture
plates on top of a layer (1 ml) of 0.5% agar. Under these conditions,
the cells did not adhere. Cells were maintained in culture for 7 days
briefly trypsinised to disaggregate clusters and viable cells counted.
Determination of intracellular Ca2þ concentration
CHO-K1 cells expressing the GRP or V1A receptor were grown to
confluence on 10 cm plates and quiesced overnight in DMEM
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containing 0.1%. FCS. Cells were trypsinised and loaded with fura-
2-tetraacetoxymethylester AME (FURA-2-AM, 1 mM) in calcium-
free Hank’s balanced salt solution for 10 min at 371C. The cells
were pelleted and resuspended in 2 ml of Hank’s balanced salt
solution containing 1.8 mM CaCl2. Fluorescence was recorded in a
fluorescence spectrophotometer (Perkin Elmer). Alternate dual
wavelength excitation at 380 and 410 nm allowed ratiometric
analysis of bound and unbound FURA-2AM when measured at
505 nm. [Ca2þ ] was calculated according to the equation
[Ca2þ ]¼K(FFmin)/(FmaxF), where F is the ratio of the
unknown sample, Fmax is the ratio after the addition of 0.1%
Triton X-100 and Fmin is the ratio after Ca
2þ chelation with 10 mM
EGTA. K is the dissociation constant for Fura-2, which is 224 nM.
Western blotting
Quiescent cell cultures in six-well plates were treated as described
in figure legends and lysed at 41C in 0.25 ml lysis buffer containing;
25 mM HEPES pH 7.4, 0.3 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.5% Triton X-100, 20 mM b-glycerphosphate, 0.5 mM dithiothrei-
tol, 1 mM sodium orthovanadate and protease inhibitors (Boeh-
ringer Mannheim, Sussex, UK; prepared as per the manufacturer’s
instructions). Lysates were clarified by centrifugation, equilibrated
for protein using BCA protein assay reagent (Perbio Science,
Cheshire, UK) and denatured by boiling (5 min) in SDS– PAGE
loading buffer. In all, 20 ml lysate/lane was resolved on 12% SDS–
PAGE gels and electroblotted onto nitrocellulose membranes.
Membranes were blocked in 3% bovine serum albumin in PBS
containing 0.05% Tween-20. ERK1/2 phosphorylation was deter-
mined using 1 : 1000 dilution of the primary antibody followed by
the appropriate HRP-labelled goat IgG (DAKO, UK) diluted
1 : 5000. Bands were visualized using enhanced chemiluminescence
(ECL plus, Amersham) and quantified using a phosphor imager
(Storm).
RESULTS
Receptor binding
To assess receptor expression, stable cultures of CHO-K1-GRP and
CHO-K1-V1A cells were incubated with the appropriate radioli-
gand, and receptor number and affinity were measured from
competition binding curves with unlabelled ligand. Figure 1 shows
that GRP receptors were expressed with Kd¼ 2.5570.84 nM and
Bmax of 11517326 sites/cell (n¼ 4). V1A receptors were expressed
at a slightly lower level with a Bmax¼ 450780 sites/cell and
Kd¼ 2.9870.71 nM (n¼ 4, Figure 1B). The substance-P analogues
SP-G and SP-D inhibited [125I]-GRP binding with affinities in
the micromolar range (SP-G Ki¼ 19.476.3mM (n¼ 4), SP-D
Ki¼ 0.6470.05mM (n¼ 4, Figure 1)). Both analogues also inhibited
V1A receptor binding ((SP-G Ki¼ 3.5070.82 mM (n¼ 4), SP-D
Ki¼ 8.5871.47mM (n¼ 4)). This data show that SP-G is relatively
(six-fold) more selective for the V1A receptor whereas SP-D is GRP
receptor selective (13-fold).
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Figure 1 Receptor binding. Gastrin-releasing peptide (A, C) or V1A (B, D) receptor expressing CHO cells were incubated with [
125I]-GRP or [125I]-AVP
for 30 min at 371C as described in Methods in the presence of various concentrations of unlabelled GRP (A), unlabelled AVP (B), SP-D or SP-G (C, D).
Results are expressed as % total binding and represent the mean7s.e.m. of four experiments performed in triplicate.
Neuropeptide receptors induce transformation
AC MacKinnon et al
524
British Journal of Cancer (2005) 92(3), 522 – 531 & 2005 Cancer Research UK
T
ra
n
sla
tio
n
a
l
T
h
e
ra
p
e
u
tic
s
Effects of V1A and GRP receptor expression on cell growth
in liquid culture and semisolid media
Figure 2A shows that in liquid culture, in the presence of 5% FCS,
the GRP and the V1A expressing cells proliferated at a similar rate
to untransfected CHOs, but on day 6 after seeding, the GRP cells
had reached a density of 4.5 106 cells per 100 mm dish. The cells
did not appear to be contact inhibited and exhibited a rounded
morphology. Cells over grew one another and significant numbers
of cells were observed to be detached and growing in clusters
(Figure 2B). Trypan blue exclusion revealed that the cells were
495% viable. A similar, though less pronounced, effect was
observed with the V1A-transfected cells, which reached a density of
3.1 106 cells per 100 mm dish. The parental cell line exhibited
normal contact inhibition and had flat fibroblast morphology and
did not show significant detachment. The end point density of
these cells was 2.1 106 cells per 100 mm dish. These observations
suggested that transfection of GRP and V1A receptors caused CHO-
K1 cells to lose contact inhibition and adopt a more transformed
phenotype. These findings led us to examine their growth in
semisolid media, which is widely regarded as being a hallmark of
the transformed phenotype. Cells were trypsinised and suspended
in 0.3% agarose in DMEM (1 104cells ml1) layered over a 0.5%
layer of agarose in DMEM. Figure 2C shows that at day 9 after
seeding, clusters of cells (46 cells) were visible with MTT staining.
The cloning efficiency was significantly higher in the GRP-
expressing cells (14.171.5%, Po0.05, ANOVA) and the V1A
receptor-expressing cells (8.571.0%, Po0.05, ANOVA) than the
vector control cells in the presence of 5% FCS (5.570.02%). In a
separate series of experiments, the effects of SP-D and SP-G were
examined (Figure 3A). At 30 mM, both analogues significantly
reduced colony formation in the GRP and V1A receptor expressing
cells but had no effect on the cloning efficiency of vector control
CHO-K1 cells. The effect of receptor expression was also examined
in an aggregation assay where cells are prevented from adhering
and form aggregates in suspension. After 6 days, cells are briefly
trypsinised and viable cells counted. These experiments showed
that expression of the GRPr and V1Ar increased anchorage-
independent growth compared to wild-type cells or vector control
cells. Similarly SP-G and SP-D were able to inhibit cell growth in
receptor expressing cells (Figure 3B). Together, these data suggest
that expression of the GRP and V1A receptors induce a more
transformed phenotype in CHO cells and induce sensitivity to
substance-P analogue-induced growth inhibition.
Chemosensitivity
The response to etoposide in control and receptor-transfected cells
was measured by MTT accumulation. Figure 4 shows that after 48 h
in culture in the absence of serum, etoposide produced a dose-
dependent inhibition of proliferation in all cell types
(IC50¼ 12.473.1, 8.172.3 and 14.274.0 mg ml1 in CHO-WT,
CHO-GRPr and CHO-V1Ar cells, respectively). Incubation with
50 nM of either bombesin or AVP added to CHO-GRPr or CHO-
V1Ar produced a small but significant protection from etoposide,
which was not observed when both neuropeptides were added to
wild-type cells (IC50¼ 13.0 and 26.9 mg ml1 in control and AVP-
treated V1Ar-expressing cells, respectively; and 6.30 and
12.7mg ml1 in bombesin-treated GRPr-expressing cells, respec-
tively). At 40 mg ml1 etoposide, vasopressin-treated V1Ar-expres-
sing cells accumulated 92% more MTT than control cells
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Figure 2 Effect of neuropeptide receptor expression on cell growth liquid growth (A) CHO-K1 cells expressing vector, the GRP or V1A receptor were
plated at a density of 1e4 cells/100 mm tissue culture dish and incubated at 371C. Cells were harvested at various times and counted. Results represent the
meanþ s.e.m. of three experiments performed in duplicate (*significantly different from vector control cells Po0.05, ANOVA). (B) Representative images
showing morphological features of transfected cells are shown. The rounded cobblestone features and higher cell density are evident in neuropeptide
receptor expressing cells compared to the elongated contact inhibited monolayer exhibited by vector transfected controls. Clonal growth vector (open bars),
GRP receptor (black bars) and V1A receptor (grey bars) transfected cells were plated at 1e
4 cells well1 in 0.3% agar in DMEM containing 1% (C) or 5% (D)
FCS. At various time points, cells were stained with MTT and colonies counted at  10 magnification. Results represent the mean7s.e.m. of three
experiments performed in duplicate (*significantly different from vector control cells Po0.05, ANOVA).
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(Po0.01). In GRPr-expressing cells, bombesin treatment caused an
increase of 52% MTT accumulation compared to untreated cells
(Po0.01). These results suggest that neuropeptide receptor
stimulation may contribute to an increase in chemoresistance.
Intracellular [Ca2þ ]i
The mobilization of calcium from intracellular stores is one of the
earliest events triggered by neuropeptide receptor activation of Gaq
leading to PLC activation and subsequent generation of IP3. In
untransfected CHO-K1 cells, neither GRP nor AVP produced a
significant change in [Ca2þ ]i (data not shown). In the CHO-GRP
cells, GRP produced a concentration-dependent increase in
[Ca2þ ]i (EC50¼ 2.0070.4 nM, n¼ 5, Figure 5A). SP-D and SP-G
produced no change in [Ca2þ ]i on their own but inhibited GRP-
induced [Ca2þ ]i elevation. Figure 5A and B show that SP-D and
SP-G inhibited GRP-induced [Ca2þ ]i with resultant pA2 values of
7.21 and 5.72 for SP-D and SP-G respectively. In V1A-express-
ing cells, AVP increased calcium mobilisation with an
EC50¼ 3.170.60 nM (n¼ 4, Figure 5C and D). As in the GRP-
expressing cells, SP-D and SP-G did not mobilise intracellular
calcium directly but inhibited the response to AVP (Figure 5C and
D). SP-G was more efficacious in inhibiting the vasopressin
response than the GRP response. PA2 values for AVP antagonism
were 7.23 and 6.53 for SP-D and SP-G, respectively. Together, these
data suggest that when stably transfected into CHO cells the GRP
and the V1A receptor effectively couple to Gaq to increase
intracellular calcium and that the substance-P analogues are
effective antagonists of this response.
ERK activation
AVP and bombesin have been shown to activate extracellular
regulated protein kinases (ERK 1 and 2) in a variety of cell types
expressing the receptors. Much of these data suggest a Gq- and
PKC-dependent mechanism although these observations may be
cell type-dependent (Della Rocca et al, 1999; Sinnett-Smith et al,
2000). Previous studies have shown that substance-P analogues
reversibly inhibit ERK activation by neuropeptides in Swiss 3T3
cells; however, our studies suggest that in rat-1 fibroblasts and in
human small-cell lung carcinoma cells (SCLC), in the absence of
bombesin, substance-P analogues can activate ERK and c-jun
kinase (JNK) in a GRP receptor-dependent manner (MacKinnon
et al, 2001). In this study, ERK activation was measured in CHO
cells expressing GRP or V1A receptors in response to the
appropriate neuropeptide or substance-P analogue. Activation
was estimated in immunoblots from stimulated lysates using a
CHO-k1 GRP V1A
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Figure 3 Effect of SP-D and SP-G on clonal growth. (A) Cells were
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(open bar) of 30 mM SP-D (black bar) or SP-G (grey bar). Results represent
the mean7s.e.m. of three experiments performed in duplicate (*sig-
nificantly different from wild-type controls Po0.05, ANOVA). Aggregation
assay. (B) Wild-type, GRPR-transfected and V1AR-transfected CHO-K1
cells were plated into low adhesion tissue culture plates on top of a layer of
0.5% agar in DMEM containing 5% FCS at a density of 5 104 ml1 in the
presence of varying concentrations of SP-G. Cells were maintained in
culture for 7 days, briefly trypsinised to dissagregate clusters and viable cells
counted by propidium iodide exclusion.
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Figure 4 Effect of neuropeptide on chemosensitivity. Wild-type CHO-K1 cells (left) and cells expressing the V1A (middle) or GRP (right) receptor were
plated at a density of 1e4 cells per well of a 96-well tissue culture plate in DMEM with 10% FCS and incubated overnight 371C. Cells were then incubated in
serum-free media containing etoposide as indicated and in the absence (filled squares) or presence of either 50 nM AVP (open squares) or 50 nM bombesin
(open circles) or both neuropeptides (wild-type cells) for 48 h at 371C. Cell viability was assessed by MTT staining. Results are expressed as % viability in the
absence of neuropeptide and are meanþ s.e.m. of four independent experiments (*significantly different from untreated etoposide control, Po0.05
ANOVA).
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phosphorylation state-specific antibody. Lysates from quiesced
cells stimulated for 10 min with either neuropeptide or SP-D or SP-
G were separated on 12% gels and blotted for pERK2 or total
ERK1/2. Figure 6A shows that bombesin stimulated ERK
phosphorylation in GRP-expressing CHO cells. Quantification of
five separate experiments showed that bombesin produced a
maximal 3.5-fold increase in ERK phosphorylation at 1 nM with an
EC50 of 0.56 nM. In V1A-expressing cells, AVP produced an increase
in ERK phosphorylation of 4.2-fold with an EC50 of 0.72 nM, which
correlated with its affinity for V1A receptors measured in binding
studies and for the stimulation of intracellular calcium. Neither
AVP nor GRP produced any stimulation of ERK phosphorylation
in untransfected CHO cells (data not shown).
SP-D and SP-G stimulated ERK activation in GRP receptor
expressing CHO cells (Figure 6B). Activation of ERK was evident at
3 mM for SP-D, but the maximal stimulation was less than that
observed with bombesin (2.8-fold for SP-D and 2.1-fold for SP-G at
50 mM). The substance-P analogues also stimulated ERK in V1A-
expressing cells. However, in these cells SP-G was more efficacious
than SP-D giving a 4.3-fold stimulation at 50 mM compared to a 2-
fold stimulation by the same concentration of SP-D. The observed
increase in ERK phosphorylation was not due to a change in total
ERK expression, as ERK1/2 immunoreactivity did not change with
drug treatment. These data show that at concentrations, which
block neuropeptide-stimulated calcium release, substance-P ana-
logues are agonists for ERK activation in GRP and V1A expressing
CHO cells.
Mechanisms of ERK phosphorylation
The mechanisms of GRP- and V1Areceptor-mediated ERK activa-
tion are not fully understood, although it has been shown in some
cell types that activation is mediated by Gq-induced PKC activation
and subsequent activation of raf. Other GPCRs have been shown to
activate ERK in a Gi and ras-dependent mechanism, which may or
may not involve activation of PI3 K (Della Rocca et al, 1999). To
examine the possible recruitment of Gi, CHO cells were incubated
overnight in quiescent media containing 100 ng ml1 pertussis
toxin. Figure 7 shows that in GRP receptor expressing cells, PTX
produced a small but nonsignificant inhibition of bombesin-
stimulated ERK activation whereas the response to 10 mM SP-D was
completely abolished (Po0.01, ANOVA). In V1A-expressing cells,
the response to AVP was not inhibited by PTX pretreatment but
the response to SP-G (20mM) was completely inhibited (Po0.01,
ANOVA). In both cell types, ERK activation by 1 mM LPA was
completely inhibited by PTX treatment (data not shown). This
differential sensitivity to pertussis toxin indicates that dual Gi/Gq-
coupled mechanisms activate the ERK 1/2 cascade via GRP and
V1A receptors expressed in CHO cells.
DISCUSSION
This study utilised a model CHO cell system for neuropeptide
receptor expression as these cells have an acceptable null
background for these receptors. The results from this work shows
that (1) GRP and V1A receptor expression leads to the development
of a transformed phenotype in CHO-K1 cells. (2) Receptor
expressing cells showed some increased resistance to the
chemotherapeutic agent etoposide and increased sensitivity to
the substance-P analogues, SP-D and SP-G. (3) SP-D and SP-G act
as biased agonists at GRP and V1A receptors. This is the first
demonstration of biased agonism at vasopressin receptors. (4)
This pharmacological activity is crucial for the antiproliferative
effect of these agents, which may be of particular benefit in more
differentiated cancers that have developed resistance to che-
motherapy.
Introduction of the neuropeptide receptors into CHO cells lead
to an increase in proliferation and an increase in the ability of cells
to grow as colonies in semisolid medium. The cells also showed a
greater propensity to grow as nonadherent clusters. Colony growth
was also evident in low serum suggesting that expression of these
receptors allows for anchorage- and serum-independent growth
consistent with transformation. Moreover, it suggests that these
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Figure 5 Intracellular calcium release. Quiescent GRP (A, B) or V1A (C, D) receptor expressing CHO cells were incubated with FURA-2AM for 15 min
at 371C and ratiometric fluorescence monitored at 371C. Concentration–response curves to bombesin were carried out in control cells and in cells
pretreated for 2 min with 1 or 10 mM SP-D (A) or SP-G (B). Concentration–response curves to vasopressin were carried out in control cells and in cells
treated with 1 or 10mM SP-D (C) or SP-G (D). Results are expressed as % maximum control response to neuropeptide and represent the mean7s.e.m. of
four experiments.
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receptors show some constitutive activity, as wild-type receptor
expression alone was sufficient to increase transformation in the
absence of exogenously added neuropeptide. The ability to observe
constitutive GPCR activity is not only determined by the intrinsic
molecular properties of the GPCR studied but also by the specific
cellular background. Apparent constitutive activity of a wild-type
GPCR may vary substantially in various systems. Differences in
GPCR expression level, GPCR desensitisation, G-protein comple-
ment and GPCR/G-protein stochiometry can all contribute to such
differences (Seifert and Wenzel-Seifert, 2002) This could explain
why GRP receptors expressed in NCM460 cells, a nonmalignant
human colon epithelial cell line, are constitutively active (Ferris
et al, 1997) but are not in other cell types (Benya et al, 1994). Our
findings are unlikely to be due to an overexpression artefact as the
receptors in this study were expressed at levels not greater than
those measured from a variety of other cancers (100–50 000 sites/
cell, Jensen et al, 2001) So at these moderate levels, wild-type
receptor was sufficient to activate downstream signals that
promote cell survival under anchorage-independent conditions.
The cells were, however, still able to respond to agonist, which
resulted in a small but significant increase in resistance to the
cytotoxic effects of etoposide. It is unclear how significant this
change in sensitivity relates to the development of chemoresistance
in vivo, but highlights an important area for future investigation.
Our previous work shows that sensitivity to AVP and GRP
increases during the progression to chemoresistance in a set of
SCLC cell lines (Waters et al, 2003). This would be analogous to the
development of autocrine and paracrine growth loops in tumour
development in vivo, with tumour cells becoming more dependent
on neuropeptide growth factors for survival and subsequently
developing chemoresistance. The mechanisms governing the
survival advantage gained in neuropeptide receptor expressing
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Figure 6 (A) ERK phosphorylation by neuropeptides. Quiescent GRP (left) or V1A (right) receptor expressing CHO cells were stimulated for 5 min with
neuropeptide at the indicated concentrations. Aliquots of cell lysate were resolved by SDS–PAGE and Western blots probed with monoclonal anti-pERK1/
2 antibody (upper panel) or polyclonal anti-ERK2 antibody (lower panel). Representative Western blots are shown. Bar graphs represent the mean optical
density (mean7s.e.m.) of four separate experiments. (B) ERK phosphorylation by substance-P analogues. Quiescent GRP (left) or V1A (right) receptor
expressing CHO cells were stimulated for 5 min with SP-D (filled bars) or SP-G (open bars) at the indicated concentrations. Aliquots of cell lysate were
resolved by SDS–PAGE and Western blots probed with monoclonal anti-pERK1/2 antibody (upper panel) or polyclonal anti-ERK2 antibody (lower panel).
Representative Western blots are shown. Bar graphs represent the mean optical density (mean7s.e.m.) of four separate experiments.
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cells are poorly understood. During colon cancer progression,
increased expression of GRP receptors leads to tumour cell
differentiation, increased motility and adhesion to extracellular
matrix via an increased activation of focal adhesion kinase (FAK)
(Glover et al, 2004). Previous reports have shown that GRP
receptors can activate insulin-like growth factor-1 receptors (IGF-
IR) leading to Akt activation in prostate cancer cells (Sumitomo
et al, 2001), a mechanism which may underlie bombesin-mediated
cell survival. In another study, human chorionic gonadotrophin
(hCG) increased ovarian cell survival by up-regulating IGF-1
(Kuroda et al, 1998). Conversely, specific bombesin antagonists
have been shown to inhibit growth and decrease EGF receptor
expression in SCLC cells (Koppan et al, 1998) and breast cancer
cells (Bajo et al, 2002). Bombesin antagonists in combination with
GHRH antagonists have also been shown to down-regulate IGF-1,
IGF-II, IGF receptors, GRP and EGF receptors in SCLC xenografts
(Kanashiro et al, 2003). There is therefore potential for neuropep-
tides to regulate growth factor signalling pathways that control
survival.
The present study shows that expression of GRP and V1A
receptors in CHO cells also leads to an increased sensitivity to
substance-P analogues. This was demonstrated by an inhibition of
clonal growth by substance-P analogues only in receptor-
transfected cells. We previously showed that substance-P analo-
gues are more effective at inhibiting growth of chemoresistant
tumour cells expressing high GRP receptor levels and can sensitise
cells to etoposide-mediated cell death (Waters et al, 2003).
Moreover, diverse tumour types expressing GRP receptors have a
greater sensitivity to SP-D (Waters et al, 2003). Together, these
data suggest that the increase in neuropeptide receptor expression
that occurs as cells become more differentiated may contribute to
the development of chemoresistance and may be exploited as a
target for drug therapy. The potential role of neuropeptide
receptors in the development of chemoresistance is an interesting
finding that requires further study.
The mechanism of action of substance-P analogues was studied
in receptor-transfected cells. Upon neuropeptide receptor transfec-
tion, the cells responded to the appropriate neuropeptide as
expected for these predominately Gq-coupled receptors. The
substance-P analogues behaved as antagonists for Ca2þ release
with potencies that reflected their affinities in receptor binding
experiments, with SP-G showing some selectivity for V1A
receptors. This may be useful in tailoring therapy to a specific
tumour phenotype in as much as SP-G may be more beneficial in
V1A receptor expressing tumours while SP-D may be better for
tumours, which express both GRP and V1A receptors. Both
neuropeptides and the substance-P analogues activated ERK in
CHO cells expressing the GRP receptor and the V1A receptor. No
ERK activation was observed in untransfected CHO cells suggest-
ing that the activation is receptor mediated. These observations
suggest that substance-P analogues act as dual efficacy receptor
agonists directing receptor signalling via the GRP and the V1A
receptor towards ERK activation while blocking liberation of
intracellular calcium. Moreover, the substance-P analogues acti-
vate ERK via Gi as the response is pertussis toxin sensitive and
more prolonged than that observed with neuropeptide (data not
shown). These data support a multitrack signalling complex
leading from neuropeptide receptor to ERK activation; where one
track is mediated by Gq and most likely involves PKC, whereas
another feeds into a Gi-mediated pathway (Wetzker and Bohmer,
2003). Although by far the majority of evidence suggests a
preference for interacting with Gq, some previous work has shown
V1A receptors coupling to Gia3 in quiescent fibroblasts and in
hepatocytes (Strakova et al, 1997; Abel et al, 2000) There is also
evidence that GRP receptors couple to Gi in pancreatic acinar cells
(Profrock et al, 1992), and that Gi mediates bombesin-stimulated
chemotaxis in monocytes (Djanani et al, 2003). Our data suggest
that in the presence of substance-P analogues, the neuropeptide
receptors exist in a conformation that is unable to activate Gq but
which is able to interact with Gi and activate ERK. These analogues
may act at a common region of the GPCRs perhaps at the receptor/
G-protein interface, which favours coupling to Gi. Although
activation of ERK is normally associated with a mitogenic response
as is seen with the neuropeptides, deregulated ERK activation has
also been shown to cause disruption of the cell cycle, growth arrest
and apoptosis. In SCLC-activated raf-1, the upstream regulator of
ERK causes growth arrest (Ravi et al, 1998). It is our hypothesis
that deregulated ERK coupled with a decrease in intracellular Ca2þ
are important factors in the growth inhibitory/apoptosis inducing
activity of substance-P analogues.
In summary, the results presented here show that neuropeptide
receptor expression leads to the development of a transformed
phenotype in CHO epithelial cells. These cells display increased
sensitivity to substance-P analogues that parallels the situation
observed in SCLC cells, which develop chemoresistance in vivo.
These analogues activate GRP and V1A receptors in such a way as
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Figure 7 Effect of pertussis toxin (PTX) on ERK phosphorylation. Confluent cultures of GRP (left) or V1A (right) receptor expressing CHO cells were
quiesced overnight in the presence or absence of 100 ng ml1 pertussis toxin. Cells were stimulated for 5 min with 30mM SP-D or SP-G or 1 nM
neuropeptide as indicated. Aliquots of cell lysate were resolved by SDS–PAGE and Western blots probed with monoclonal anti-pERK1/2 antibody (upper
panel) or polyclonal anti-ERK2 antibody (lower panel). Representative Western blots are shown. Bar graphs represent the mean optical density
(mean7s.e.m.) of four separate experiments (*significantly different from untreated control, Po0.05 ANOVA).
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to cause activation of only a subset of possible downstream signals.
They are competitive antagonists for PI hydrolysis mediated via Gq
but have agonist activity that results in activation of ERK via Gi.
This presents a novel pharmacological mechanism whereby
substance-P analogues utilise the normally mitogenic neuropep-
tide receptors to transduce an antiproliferative and apoptogenic
cell signal. Moreover, the concentration of SPG used in this study
was detected in patient plasma following administration with no
noticeable toxicity (Clive et al, 2001), suggesting therapeutic doses
can be achieved clinically. Development of these agents may
provide a unique opportunity to treat SCLC and may be of
particular benefit for tumours that have developed resistance to
chemotherapy.
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